Bryce Carmine

Bryce worked with Eli Lilly & Co for over 36 years and was an Executive Committee member and an Officer of the Company. He retired as Executive VP, Eli Lilly and Co & President of Lilly Bio-Medicines in December 2011.

​

Bryce was responsible for strategy and operations for the Lilly Bio-Medicines Business Unit, which included both clinical development of late-stage products across multiple therapeutic areas and regional sales and marketing operations for the United States, Japan, the European Union, Canada, and Australia / New Zealand. He also was responsible for the Lilly Global Marketing organisation.

​

Prior to the above role, he held the position of Executive Vice President, Global Marketing and Sales, which encompassed all therapeutic areas and the operational responsibilities for the global pharmaceutical division.

​

Bryce has had extensive product development leadership roles overseeing post proof-of-concept global development teams for the entire Lilly late-stage pipeline across all therapeutic categories. During his career, he also held multiple operational roles as President of Lilly Japan, Managing director of Australia/New Zealand and General Manager of a Joint Venture in South Korea.

​

Bryce contributed in leadership positions to the pharmaceutical industry associations internationally. Currently, he is a member of the Deans Council for Indiana University School of Public Policy & Environmental Affairs, Indiana USA and a Board Director of Kazia Therapeutics Ltd. Bryce was born in New Zealand, where he gained his B.Sc. in biochemistry from Massey University. He currently resides in both Chicago and Sydney.